PubRank

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Clinical Trial ID NCT00004067

PubWeight™ 67.09‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00004067

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 33.60
2 Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012 4.57
3 Trastuzumab in the treatment of breast cancer. N Engl J Med 2005 3.86
4 Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007 3.00
5 Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007 2.33
6 Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 2013 2.28
7 Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014 2.24
8 Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol 2015 2.17
9 The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005 2.13
10 A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007 2.09
11 Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015 1.99
12 Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006 1.65
13 Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007 1.40
14 Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010 1.05
15 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
16 Moving forward: Herceptin in the adjuvant setting. Oncology 2002 0.89
17 Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008 0.87
18 Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev 2015 0.81
19 Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. J Natl Cancer Inst 2015 0.75
20 Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016 0.75
Next 100